Welcome to: Beijing Dongfang Baitai Biotechnology Co., Ltd
CN
About
Position:
Homepage
/
About

东方百泰 Company profile

北京东方百泰生物科技股份有限公司

北京东方百泰生物科技股份有限公司成立于2011年,坐落于亦庄经济技术开发区,公司总占地面积6万平方米,是国内的抗体药物研发、生产及销售企业。公司产品类别主要以全人源单抗、人源化单抗、双特异抗体、抗体融合蛋白、治疗性疫苗等为主,适应症涵盖恶性肿瘤、糖尿病、自身免疫性疾病(类风湿性关节炎、银屑病、强直性脊柱炎等)、高血脂症、哮喘等众多高发性疾病。

 

公司拥有上百人专业抗体研发团队,布局了20多余项研发管线,先后承担了多项国家“重大新药创制”、部委专项课题和“863”计划等十一五、十二五重点项目。东方百泰始终将"品质与创新"作为企业的永恒追求。公司始终坚持以创新为企业发展的源动力,注重产业转化,其位于北京亦庄新的大规模产业基地正在建设中,总投资将达15亿,其中一期占地30亩,届时将建成一条3*3000L,符合中国、美国GMP要求的先进水平的抗体生产线。预计2022年投入使用。

关于我们页面-企业简介-Company profile

Time of issue:2022-04-07 10:00:36

DONGFANG BAITAI Company profile

Located in Yizhuang’s Economic and Technological Development Area with a total area of about 60000 square meters, Eastern Biotech was founded in 2011 and became a leading biomedical R&D, production and sales company in China. The company's product categories include full human monoclonal antibody, humanized monoclonal antibody, bispecific antibody, antibody fusion protein, therapeutic vaccine, to name a few that target prevalent diseases such as malignant tumors, diabetes, autoimmune diseases (rheumatoid arthritis, psoriasis, ankylosing spondylitis, etc.), ophthalmic diseases, respiratory diseases, etc.

Here at Beijing Eastern Biotech, we have a biological drug research and development team with more than 100 people who laid out more than 20 research and development pipelines, obtained 7 approval documents for clinical trials of new drugs, and are conducting clinical trial research. We have undertaken a number of national "major new drug development", special projects of various ministries and commissions, the "863" plan and other key projects such as the 11th and 12th Five Year Plan. We always hold "quality and innovation" as the eternal pursuit and source of power for the company and remain attentive towards changes in the industry.
Our new large-scale industrial base in Yizhuang, Beijing, is under construction with a total investment of 1.5 billion yuan. The first phase covers an area of 30 mu (about 4.9 acres) where a 3 * 2000L mammal batch cultivation production line will be built. It will meet the advanced requirements of China and the United States GMP, and it is expected to be officially put into use in 2023.
Dongfang Baitai Biopharmaceutical Co., Ltd. (or Eastern Pharmaceutical), a subsidiary of Eastern Biotech, is one of the earliest companies to be engaged in antibody drug development in China. Its core product Tai Xin Sheng® (nimotuzumab) is the first humanized monoclonal antibody drug targeting nasopharyngeal cancer China, and it has a therapeutic effect on many other cancers such as: head and neck, pancreatic, breast, glioma, non-small cell lung, etc. It was added to the Chinese Pharmacopoeia in 2015 and the national medical insurance in 2017, significantly contributing to the field of biomedical antibodies in China!
Eastern Biotech has been successively awarded the titles of "Beijing Engineering Laboratory of Antibody Project" and "Beijing Engineering Research Center of Antibody Drugs". It is not only the "Beijing International Science and Technology Cooperation Base for New Antibody and Therapeutic Protein Drugs", but also the "National International Science and Technology Cooperation Base for Advanced Technologies of New Antibody and Therapeutic Protein Drugs". We have successively established a "Postdoctoral Scientific Research Workstation" a "Academician Expert Workstation", and we are certified by the national intellectual property management system and the International Organization for Standardization (ISO 9000).
 

 

 

2011year

Date of establishment

 

 

 

 

 

20+

R&D pipeline layout

 

 

 

 

 

50%+

Percentage of doctors and masters

 

 

 

 

 

100+

Invention patent

 

 

 

 

 

3*2000L

Large scale production line

 

 

 

关于我们页面-企业文化-The enterprise culture

Time of issue:2022-07-11 14:16:53

The enterprise culture

Corporate mission

      

Gather the power of biomedicine

Create a healthy life for human beings

Corporate philosophy

      

The Doctors

The conscience of the druggist

Corporate Vision

      

Protect life and health

Become an international first-class pharmaceutical group with leading technology

Core values

      

Responsibility: responsibility, integrity and perseverance
Quality: profession, reputation and pursuit
Innovation: exploration, attitude, change
Health: spirit, life, care

 

关于我们页面-发展历程-The development course

Time of issue:2022-07-11 14:17:36

The development course

2022  |

   ●   Dongfang Baitai has been certified by ISO9000(Quality Management system certification, environmental management system certification and Occupational health and safety management system certification).

2021  |

   ●   Top 100 Private Enterprises in Beijing 2020

   ●  Dongfang Baitai has been recognized as "Beijing specialized in special and new small giant Enterprise".

   ●  Dongfang Baitai won the title of "China's New Pharmaceutical Innovation Force in 2021".

   ●  JY025 won the "China Patent Excellence Award".

      Dongfang Baitai won the "First Prize of Independent Innovation Achievements of Capital Employees in 2020".

2020  |

   ●   Dongfang Baitai was recognized as "Beijing Enterprise Technology Center"
   ●   Dongfang Baitai was recognized as "Municipal Employee Innovation Studio for bio-drug Development of Major Diseases".
   ●   Dongfang Baitai was recognized as "Municipal Employee Innovation Studio for bio-drug Development of Major Diseases".

   ●   JY016 won the "14th Beijing Innovation Competition Public Innovation Award"

   ●  JY09 won the 21st China Patent Silver Award

   ●   Dongfang Baitai was recognized as "Beijing Intellectual Property Demonstration Unit"

   ●"Beijing Dongfang Baitai Biotechnology Co., LTD." completed the share reform and changed its name to "Beijing Dongfang Baitai Biotechnology Co., LTD."

 

2019  |

   ●Dongfang Baitai is recognized as the "Home of Science and Technology Workers"
   ●   Dongfang Baitai won the Second Prize of "2018 Capital Employees' Independent Innovation Achievements"
   ●   Dongfang Baitai won the second Prize of "2019 Maker China Beijing smes Innovation and Entrepreneurship Competition" (Enterprise Group)
   ●   Dongfang Baitai was identified as "Industrial Enterprise Intellectual Property Application Pilot Enterprise"

 

2018  |

   ●   Dongfang Baitai won the "National Intellectual Property Management System Certification"
   ●   JY025 has been approved for clinical trials
   ●   Antibody drug research and development and industrialization base engineering capping

 

2017  |

   ●   Academician expert Research station was officially established

   ●   The post-doctoral research station was officially established

   ●   JY09 won the first prize of "2016 Capital Employees Independent Innovation Achievement"

   ●   JY028(AMD) has been approved for clinical trials

   ●   Antibody drug research and development and industrialization base project is under construction

   ●   JY026 has been approved for clinical trials

   ●  JY028 has been approved for clinical trials

2016  |

   ●   Dongfang Baitai has been recognized as the "International scientific and Technological Cooperation Base for New Antibody and therapeutic protein Drug Frontier Technology".

   ●   "JY09" won "T100 New Products and New Technology"

   ●   "JY09" won "T100 New Products and New Technology"

   ●   "JY09" has been approved for clinical trials

2015  |

   ●   The holding subsidiary "Baitai Biological Pharmaceutical Co., LTD." marks the 15th anniversary of its establishment

   ●   Dongfang Baitai was recognized as the "Innovation Studio for Biological drug Development Staff".

2014  |

   ●   Dongfang Baitai was recognized as "Zhongguancun High-tech Enterprise"

   ●   Dongfang Baitai was recognized as "Beijing International Science and Technology Cooperation Base for New Antibody and Therapeutic Protein Drug Frontier Technology".

   ●   Dongfang Baitai won the "Patent Pilot Certificate"

2013  |

   ●   Dongfang Baitai was recognized as "Beijing Engineering Research Center for Antibody Drugs". 

 

2011  |

   ●   Dongfang Baitai was identified as "Beijing Engineering Laboratory of Antibody Engineering"

   ●   Dongfang Baitai was recognized as "Beijing Genetic Engineering Antibody Drug Engineering Technology Research Center"

   ●   Beijing Dongfang Baitai Biotechnology Co., LTD was established 

 

2008  |

   ●   "Beijing Jingyi Taixiang Technology Development Co., LTD." was restructured to prepare for the establishment of "Beijing Dongfang Baitai Biotechnology Co., LTD." 

 

 

 

  

企业文化 The enterprise culture

北京东方百泰生物科技股份有限公司

使命:凝聚生物医药力量,创享人类生活健康

 

理念:医者仁心,药者良心

 

愿景:守护生命健康,成为技术的制药集团

核心价值观

责任: 担当、诚信、坚守,乃企业立足之根本。

品质:  专业、信誉、追求,乃企业永恒之基石。

创新:  探索,态度,变革,乃企业长青之保障。

健康:  精神,生命,关爱,乃企业奋斗之目标。

发展历程 The development course

北京东方百泰生物科技股份有限公司
In 2022, Dongfang Baitai Innovation and Transcendence, and Open a New Prospect

2022

Innovation drives the regeneration of fusion engine. Recently released the patent entrepreneurship project of Zhongguancun National Intellectual Property System Demonstration Park in 2022. Good news came again that Dongfang Baitai was selected successfully. Innovation is the main color and background of Dongfang Baitai in 2022. It is the key to open a bright future. We are ready to move forward. 
Great! Dongfang Baitai successfully passed the ISO three system certification

2022

Be vigorous and resolute, and be steady and farsighted! On March 24, 2022, it was comprehensively, rigorously and meticulously audited by experts. Dongfang Baitai successfully passed the ISO three system certification. This is a sign that the Oriental Baitai brand has reached international standards. It is also the embodiment of the company's quality, environment, occupational health and safety management and further strengthening and improvement.
Once again won the prize! Dongfang Baitai's High Value Invention Patent Strength Becomes Outstanding

2022

Good news spread frequently, and scientific and technological innovation yielded fruitful results. The second batch of "Zhongguancun enterprise patents, technical standards and other support funds" recently released, Dongfang Baitai stood out. It was recognized as a high-value invention patent for Zhongguancun technology-based SMEs. This is the growth witness of Dongfang Baitai's innovative development. This is also a reflection of its responsibility to actively implement the ESG development concept.
Beijing Association of Science and Technology Innovation Service Center Visits Dongfang Baitai

2022

On the morning of December 6, a delegation led by the Innovation Service Center of Beijing Association of Science and Technology visited Beijing Dongfang Baitai Co., Ltd. The general manager of Dongfang Baitai and the heads of relevant departments warmly received the delegation from the Innovation Service Center. Shen Zhanlong, the chief physician of gastrointestinal surgery in the People's Hospital of Peking University, Qiu Yongping, the director of foreign cooperation in the Science and Technology Development Department of Tsinghua University, Lan Xi, the medical school of Tsinghua University, and other experts also visited.
Post training activities | Strengthen self construction and promote innovative development

2022

Strengthen self-construction to promote innovative development.  On November 25th, guided by the Federation of Trade Unions of Beijing Economic and Technological Development Zone, the training activity of Dongfang Baitai came to a successful conclusion.  Improve skills and be based on posts.
Leaders from the Personnel Organization Department of the Development Zone, the Science and Technology Innovation Bureau and the Yiqi Service Port visited Dongfang Baitai and Baitai Biological Research

2022

On the morning of September 8, Yu Miao, Minister of the Personnel Organization Department of the Development Zone, Jin Guangze, Director of the Science and Technology Innovation Bureau, and leaders of Yiqi Service Port visited Dongfang Baitai and Baitai Bio. They deeply investigated the development and operation of the enterprise and the development of the company's party building, and understood the urgent needs in the process of enterprise development in detail. Bai Xianhong, Chairman of Dongfang Baitai and Baitai Bio, He Lihua, Executive Deputy General Manager, and heads of relevant departments of the company warmly welcomed the visiting leaders.
Dongfang Baitai won the list of "2021 China's pharmaceutical innovation power"

2022

On August 1, the list of "China's pharmaceutical innovation force in 2021" was unveiled at the 2021 (38th) National Pharmaceutical Industry Information Annual Conference. Dongfang Baitai won the list with its outstanding R&D strength and innovation spirit. A total of 12 well-known innovative enterprises were selected. It is the representative of the most innovative new force in China's pharmaceutical industry.
Dongfang Baitai ascends the podium again

2022

The "Bank of Beijing Cup China • Beijing Innovation and Entrepreneurship Competition Final" was held in Changyang Art Museum, Fangshan District, Beijing on August 29, 2019. There are more than 1000 entries in six major industries. After fierce competition, 67 high-quality projects emerged to reach the peak of the final. These are top project products in various industries in Beijing. Beijing Dongfang Baitai [Exendin-4 Fc antibody fusion protein (JY09) project] broke through the tight encirclement and won the second prize in 67 projects selected at all levels in Beijing.
Dongfang Baitai won the second prize in the final of the "5th Beijing Innovation and Entrepreneurship Biomedical and Artificial Intelligence Theme Competition"

2022

On August 18, 2019, the final of the "Fifth Beijing Innovation and Entrepreneurship Biomedical and Artificial Intelligence Theme Competition" was held in Changping District, Beijing. Dongfang Baitai attended and won the second prize.
Dongfang Baitai was honored as the winner of the Maker Beijing 2019 Innovation and Entrepreneurship Competition

2022

On August 14, the 2019 "Maker China" Beijing SME Innovation and Entrepreneurship Competition and "Maker Beijing 2019" Innovation and Entrepreneurship Competition successfully ended in Beijing. After two months of fierce competition, 30 winners were finally determined. They won the first, second and third prizes of the Enterprise Group and Maker Group respectively. Bai Yi, General Manager of Beijing Dongfang Baitai, attended the meeting and took the stage to receive trophies and bonuses.
Dongfang Baitai Attends Qianhai Master Fund Private Equity Investment Summit Forum and Partner Conference

2022

On April 25, 2019, Qianhai Master Fund held the Henan Private Equity Investment Summit Forum and 2018 Annual Partner Conference, "Focusing on the Science Innovation Board and Cultivating New Kinetics", in Sofitel International Hotel, Zhengzhou. Bai Yi, General Manager of Dongfang Baitai, was invited to attend and won the Best Performance Award of the Best Investment Case Award.
Leaders from the Science and Technology Department of the National Health Commission and the Registration Department of the State Food and Drug Administration visited Dongfang Baitai

2022

On August 8, 2019, Liu Dengfeng, Director of the Department of Science and Technology of the National Health Commission, Zhang Hui, Director of the Biological Products Division of the Registration Department of the State Food and Drug Administration, and other leaders visited Beijing Dongfang Baitai Biotechnology Co., Ltd. and Baitai Biological Pharmaceutical Co., Ltd. for in-depth investigation. Bai Xianhong, Chairman of Baitai Bio, and Bai Yi, General Manager of Dongfang Baitai received warmly.
北京市科委领导走访调研东方百泰

2022

近日,北京市科委副主任郑焕敏一行莅临北京东方百泰生物科技股份有限公司及百泰生物药业有限公司,深入调研企业研发进展,实地考察公司生产车间并进行了亲切交流。北京生物技术和新医药产业促进中心主任潘悦、副主任程伟等一行6人陪同调研;东方百泰董事长白先宏、总经理白义热情接待了来访领导。
Dongfang Baitai Appears at the Third Beijing International Medical Health Innovation Exhibition

2022

From October 29 to 31, the "2018 Third Beijing International Medical Health Innovation Exhibition" (IMHI2018) hosted by Beijing Pharmaceutical Industry Association was held in Beijing National Convention Center. With the theme of "opening up, innovation and development", hundreds of enterprises concentrated on demonstrating the fruitful achievements in the field of medicine and health since China's reform and opening up. Dongfang Baitai was invited to make an appearance.
Dongfang Baitai was invited to the Biomedical Hundred People Forum to discuss the new policy of medicine to drive industrial innovation!

2022

On November 24, 2018, the Biomedical Hundred Talents Forum, jointly held by the National Health and Family Planning Commission Medical and Health Science and Technology Development Research Center and the Beijing Science and Technology Cooperation Center and the Beijing Society of Biotechnology, opened in Beijing. Bai Yi, General Manager of Beijing Dongfang Baitai Biotechnology Co., Ltd., was invited to attend and speak.
Heavy! Dongfang Bataicumab got another clinical approval!

2022

On May 27, 2017, the monoclonal antibody drug "recombinant humanized anti VEGF monoclonal antibody injection" independently developed by our company obtained the clinical approval issued by the State Food and Drug Administration. The approved clinical indication is wet (neovascular) age-related macular degeneration (AMD).
The labor model around us

2022

Recently, the 2018 Advanced Model Person Commendation Activity of Beijing Economic and Technological Development Zone with the theme of "Yizhuang Model · Labor Anthem" was held in the report hall on the first floor of Yizhuang Broad Building. Relevant leaders of the Working Committee and Management Committee of the Development Zone, as well as outstanding enterprise talents and collective representatives from all walks of life in the Development Zone attended the meeting. Bai Yi, the general manager of our company, won the honor of "a good manager who loves employees"; Bai Yongqin, an employee of our company, has won the honor of "a good employee who loves the enterprise".
Leaders of the development zone visited Dongfang Baitai for investigation and guidance

2022

Recently, Zhang Jihong, member of the Standing Committee of Daxing District, member of the Working Committee of the Development Zone, and deputy director of the Management Committee, Liu Li, director of the Development and Reform Bureau of the Development Zone, and leaders of the Science and Technology Bureau and the Intellectual Property Office of the Development Zone visited Beijing Orient Baitai Biotechnology Co., Ltd. and Baitai Biopharmaceutical Co., Ltd. They investigate and guide the work of enterprises. Bai Xianhong, Chairman of Dongfang Baitai, Bai Yi, General Manager and other company leaders warmly welcomed Director Zhang Jihong and his delegation. The symposium was held and accompanied to inspect the company's production workshop and R&D platform.
Dongfang Baitai obtained another clinical approval document for anticancer drugs

2022

At the end of July 2018, the McAb drug "Recombinant anti VEGF R2 whole human monoclonal antibody injection" JY025 independently developed by Dongfang Baitai was approved by the State Food and Drug Administration (CFDA). The approved clinical indications are non-small cell lung cancer, gastric cancer and liver cancer.
Dongfang Baitai academician expert workstation was established

2022

In order to build a strategic highland of "scientific and technological innovation, product research and development, and talent gathering" and improve the technical level of the enterprise, Dongfang Baitai has established an enterprise academician expert workstation. Recently, Dongfang Baitai whole human monoclonal antibody drug development academician expert workstation was officially licensed.
Another breakthrough in the research and development of Dongfang Baitai antibody!

2022

At present, bispecific antibodies are rare in China. There is no corresponding product on the market. With the maturity of bispecific antibody technology and increasing investment, bispecific antibody has gradually become a new upstart in antibody industry.
Dongfang Baitai was approved to set up a postdoctoral research workstation

2022

Recently, with the approval of the Ministry of Human Resources and Social Security and the National Postdoctoral Management Committee, Beijing Dongfang Baitai Biotechnology Co., Ltd. successfully established a postdoctoral research workstation. It is used to further cultivate and introduce high-level scientific and technological talents, to help promote the company's intensive R&D projects, and also marks a new step in the company's scientific research strength.
Dongfang Baitai successfully passed the national intellectual property management system standardization certification

2022

In September 2018, Beijing Dongfang Baitai Biotechnology Co., Ltd. successfully passed the National Intellectual Property Management System (IPMS) standardization certification and was awarded the Intellectual Property Management System Certification. The company has become one of the first enterprises in Beijing to pass the certification. It is also one of the few "certified enterprises" in Beijing Economic and Technological Development Zone.
The father and son in the development zone have been praised by Chinese people

2022

In the new medical insurance drug list released in September this year, the emergence of four anti-tumor monoclonal antibody drugs has aroused people's attention to monoclonal antibody drugs.
Dongfang Baitai Appears in 2018 National Mass Entrepreneurship and Entrepreneurship Week

2022

The national "Mass Entrepreneurship and Innovation" activity week in 2018 with the theme of "mass entrepreneurship and innovation to promote upgrading and pay for excellence" was held in Beijing Yizhuang Branch from October 11 to 12 in B1 Hall of Beijing Yichuang International Convention and Exhibition Center. The high-tech products from many enterprises in the development zone and the innovation and entrepreneurship stories of excellent enterprises are exhibited here. As a high-tech enterprise in Yizhuang Development Zone, Beijing Dongfang Baitai Biotechnology Co., Ltd. was invited to appear in the "Biomedical" section of the exhibition. At the same time, he was awarded the award of "2018 Yizhuang Tomorrow Star" at the opening ceremony.
Dongfang Baitai PD-1 Project won the Excellent Award of Beijing Tianjin Hebei Collaborative Innovation

2022

In May 2017, the Beijing Tianjin Hebei Collaborative Innovation Award Selection and Award Ceremony of the 11th Beijing Invention and Innovation Competition was held in Beijing Guangda Building. During the meeting, the special prize for the coordinated development of Beijing, Tianjin and Hebei in the 11th Beijing Invention and Innovation Competition was reviewed on the spot. All the awards were announced and awarded. The entry project of Beijing Dongfang Baitai Biotechnology Co., Ltd.: a monoclonal antibody against PD-1 and its winning method won the Beijing Tianjin Hebei Collaborative Innovation Excellence Award.
Double happiness! Dongfang Baitai adalimumab Bio-similar Drugs Obtained Clinical Approval!

2022

Two products of Beijing Dongfang Baitai Biotechnology Co., Ltd. (hereinafter referred to as " Dongfang Baitai"), anti-vascular endothelial growth factor (VEGF) humanized antibody medicine JY028 and anti-tumor necrosis factor-α (TNF-α) all-human antibody medicine JY026, have been approved by china food and drug administration (CFDA) for clinical trials within half a month. It can be described as double happiness! At present, JY09, JY028 and JY026 have entered clinical research.
Dongfang Baitai anti-cancer drug has obtained clinical approval!

2022

Beijing Dongfang Baitai Biotechnology Co., Ltd. is a cutting-edge biotechnology company focusing on the research and development of humanized monoclonal antibodies. The anti VEGF humanized antibody JY028, the company's product under research, has recently obtained the approval document for drug clinical trials issued by the State Food and Drug Administration (CFDA). It means that the anti-cancer drugs of Dongfang Baitai can officially carry out clinical research in China, which is an important step for the product to go on the market. This is another major breakthrough of Dongfang Baitai after obtaining the clinical approval document of long-acting diabetes biological drug JY09.
Chen Chuanhong, Director of Major Projects Office of the Ministry of Science and Technology, visited Dongfang Baitai

2022

On November 17, 2016, Chen Chuanhong, Director of Major Special Projects Office of the Ministry of Science and Technology and Secretary of the Party Branch, visited Beijing Orient Biotech Co., Ltd. and Biotech Pharmaceutical Co., Ltd. to investigate the latest progress of major innovative drug projects. Yang Zhe, Deputy Director of the Major Special Projects Office of the Ministry of Science and Technology, Xie Min, Inspector of the Major Special Projects Office of the Ministry of Science and Technology, Deputy Secretary of the Party Branch, Li Xiao, Director of the Comprehensive Coordination Office of the Major Special Projects Office of the Ministry of Science and Technology, Shen Yonggang, Deputy Director of the Management Committee, accompanied the investigation.
Dongfang Baitai won the top 100 "coolest black technology" in China in 2016

2022

On November 11, 2016, the grand ceremony of "T100 New Technology and New Product Innovation Action" was held in Beijing National Convention Center. The "Top 100 Black Science and Technology Companies in China" were unveiled on the spot. Beijing Dongfang Baitai Biotechnology Co., Ltd. won the honor by virtue of its major new drug with independent intellectual property rights, Exendin-4 immune fusion protein, a long-acting drug for diabetes.
Investigation and guidance of Kunming party and government delegation Dongfang Baitai

2022

Recently, Bao Jianbin, member of the Standing Committee of the CPC Kunming Municipal Committee and vice mayor of Kunming, led the party and government delegation of Kunming to visit Beijing Dongfang Baitai Biotechnology Co., Ltd. They conducted in-depth research on the production, operation and technological innovation of enterprises and held symposiums for cordial exchanges.
Warmly welcome Vice Mayor Lin Keqing to visit Dongfang Baitai

2022

On October 24, 2016, a delegation led by Lin Keqing, Vice Mayor of Beijing, visited Beijing Orient Biotech Co., Ltd. and Biotech Pharmaceutical Co., Ltd. They conducted in-depth research on the R&D progress of the enterprise, visited the production workshop of the company on the spot, and had a cordial exchange.
Dongfang Baitai was selected as a backup enterprise of "G20 Project" in Beijing's biomedical industry

2022

In September 2016, the Beijing Municipal Science and Technology Commission released the list of the first batch of G20 enterprises and G20 backup enterprises during the "13th Five Year Plan" period. Beijing Dongfang Baitai Biotechnology Co., Ltd. was successfully selected as a G20 backup enterprise.
Dongfang Baitai long-acting diabetes biological class I new drug obtained clinical approval

2022

In April this year, the clinical approval document of the State Food and Drug Administration (CFDA) was obtained for the application of JY09 Exendin-4 fusion protein, a diabetes treatment drug, by Beijing Dongfang Baitai Biotechnology Co., Ltd. (hereinafter referred to as "Dongfang Baitai"). At present, the voucher preparation is completed. The breakthrough of this technology will break the monopoly of imported antibody drugs in China for a long time. This marks another important milestone in the field of Dongfang Baitai anti diabetes series drugs.
JY09 project won the gold medal of Beijing Invention and Innovation Competition

2021

In May 2016, the 10th Beijing Invention and Innovation Competition was held in Guotu Art Center. The competition announced and awarded all the awards of the 10th competition. The participating project of Beijing Dongfang Baitai Biotechnology Co., Ltd. is the long-acting Exendin-4 immune fusion protein. Dongfang Baitai JY09 project won the gold medal of Beijing Invention and Innovation Competition.
 2011年4月
由北京市发展和改革委员会审批通过的:北京市发改委的第一批工程实验室----抗体工程北京市工程实验室正式建成。
2011年6月
由北京市科学技术委员会审批通过的:北京市基因工程抗体药物工程技术研究中心正式建成。
2011年10月
北京东方百泰生物科技股份有限公司成立。
2013年11月
东方百泰控股百泰生物药业有限公司,成为百泰生物第一大股东。东方百泰在创新型抗体研发领域的优势地位得到巩固,品牌影响力进一步提升。
2013年9月
获得北京经济技术开发区核心区1-4街区48F1地块的土地使用权,计划建设新的东方百泰抗体研发生产基地。
2013年11月
由北京市发展和改革委员会审批通过的:抗体药物北京市工程研究中心
2014年3月
北京经济技术开发区管委会批准进行增资扩股,公司性质由内资转为中外合资企业。
2014年8月
北京经济技术开发区核心区1-4街区48F1地块开始破土动工,目前一期项目已经结束。新生产基地将配备的抗体研发与生产设备、平台,各方面水平将得到大幅提升。
2015年9月
东方百泰控股子公司百泰生物药业有限公司成立15周年,举行隆重庆典,对多年来百泰生物品牌影响力予以肯定,也对公司发展所取得得成绩给予认可。
Previous page
1

Follow us

1

Follow the official WeChat official account

Or search "Oriental Baitai"

More exciting waiting for you!

Address: No. 2, Rongjing East Street, Beijing Economic and Technological Development Zone
Tel.: 010-51571019
Email: ebt@east-bt.com

Copyright 2021 Beijing Dongfang Baitai Biotechnology Co., Ltd    SEO    京ICP备2023010711号-1

Beijing Dongfang Baitai Biotechnology Co., Ltd

Online customer service
Customer service hotline
010-51571019 010-51571019
Service time:
8:30 - 17:30
Customer service group:
在线客服